Global Chemotherapy Induced Neutropenia Treatment Market by Type (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others), By Application (Hospitals, Ambulatory Surgical Center, Diagnostic Centers) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
The Global Chemotherapy-Induced Neutropenia Treatment Market size is predicted to reach $1.1 billion by 2028. This represents an impressive growth opportunity for companies in the healthcare space as the global population ages and becomes increasingly aware of cancer risks.
Chemotherapy-induced neutropenia (CIN) is a temporary condition that develops during and after chemotherapy treatment. Patients may experience fever, chills, skin rashes, mouth sores, or bone marrow suppression. CIN can be prevented by administering white blood cells before the start of chemotherapy as well as the following chemotherapy with colony-stimulating factor erythropoietin hormone transfusions if needed.
On the basis of Types, the market is segmented into Animal Therapies, Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, and Others.
Animal Therapies:
Animal therapy is a type of treatment for chemotherapy-induced neutropenia in which the patient receives animal-specific immune globulin (ASIG) or intravenous gamma globulin (IVGG). ASIG refers to antibody products that are obtained from plasma donated by animals.
The main source for these antibodies comes from sheep, horses, and cows. The collected blood will be filtered and treated in order to remove any infectious agents before being used as an infusion product. The resulting product can then be administered either intravenously or intramuscularly injection depending on specific case needs. IVG primarily helps produce antibodies against toxins such as snake bites, rabies infection, or tetanus bacteria exposure.
Antibiotic Therapy:
Antibiotic therapy uses antibiotics to treat and prevent infections caused by bacteria. Antibiotics work by killing or preventing the growth of bacteria that cause illness in people, animals, or plants.
Colony-Stimulating Factor Therapy:
C-SF (colony-stimulating factor) therapy is a treatment for chemotherapy-induced neutropenia, which is an immune system disorder. C-SF stimulates the production and function of granulocytes that help fight infection in the body.
It also helps to prevent infections from developing in those with low levels of white blood cells called neutrophils or "neutros," as well as patients undergoing cancer treatments such as radiation or chemotherapy who have been exposed to high doses of chemical agents that causes damage to bone marrow stem cells responsible for producing new white blood cells.
Granulocyte Transfusion:
Granulocyte transfusion, also known as a neutrophil infusion is a treatment for chemotherapy-induced neutropenia. Granulocytes are white blood cells that help in fighting infections and may be lost during or after chemotherapy treatments. This loss of these important immune cells can lead to an increased risk for infection and fever from bacteria. Granulocyte infusions replace the missing granulocytes with healthy ones drawn from either red blood cell donors or stored frozen products until they're needed again due to chemotherapy-induced neutropenia (CIN).
On the basis of Applications, the market is segmented into Hospitals, Ambulatory Surgical Center, and Diagnostic Centers.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America leads in revenue generation from the global market with a substantial contribution from Europe due to rising awareness among cancer patients about their disease which has led them to get treated at hospitals in these regions.
The Asia Pacific is also expected to be a major contributor owing to high incidence rates of cancer as well as a rise in disposable incomes leading to a greater number of people undergoing chemotherapy treatment. Latin American region will offer significant growth opportunities for this market owing to rising awareness in the region and increasing cancer incidence rates.
Growth Factors For The Global Chemotherapy-Induced Neutropenia Treatment Market:
A key driver for the growth of this market is a rise in disposable incomes leading to a greater number of people undergoing chemotherapy treatment which has led to increased demand for neutrophil granulocytes transfusion, antibiotic therapy, or colony-stimulating factor therapies which have emerged as viable options following a decline in success rate due to rising drug resistance among cancer patients.
Up Market Research published a new report titled “Chemotherapy Induced Neutropenia Treatment Market research report which is segmented by Types (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others), By Applications (Hospitals, Ambulatory Surgical Center, Diagnostic Centers), By Players/Companies Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy’s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals”.
Report Scope
| Report Attributes | Report Details |
| Report Title | Chemotherapy Induced Neutropenia Treatment Market Research Report |
| By Type | Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others |
| By Application | Hospitals, Ambulatory Surgical Center, Diagnostic Centers |
| By Companies | Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy’s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 238 |
| Number of Tables & Figures | 167 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Chemotherapy Induced Neutropenia Treatment Market Report Segments:
The market is segmented by Type Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others and By Application Hospitals, Ambulatory Surgical Center, Diagnostic Centers.
Some of the companies that are profiled in this report are:
- Amgen
- Sanofi
- Novartis AG
- Baxter International
- Teva Pharmaceuticals Industries
- Apotex
- Dr. Reddy’s Laboratory
- Biogenomics Limited
- Ligand Pharmaceuticals
Chemotherapy Induced Neutropenia Treatment Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Chemotherapy Induced Neutropenia Treatment Market
Overview of the regional outlook of the Chemotherapy Induced Neutropenia Treatment Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Chemotherapy Induced Neutropenia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Chemotherapy Induced Neutropenia Treatment Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Antibiotic Therapy
2. Colony-Stimulating Factor Therapy
3. Granulocyte Transfusion
4. Splenectomy Procedure
5. Others
7. By Application:1. Hospitals
2. Ambulatory Surgical Center
3. Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chemotherapy Induced Neutropenia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Chemotherapy Induced Neutropenia Treatment Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemotherapy Induced Neutropenia Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemotherapy Induced Neutropenia Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemotherapy Induced Neutropenia Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemotherapy Induced Neutropenia Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemotherapy Induced Neutropenia Treatment Market Size & Forecast, 2018-2028
4.5.1 Chemotherapy Induced Neutropenia Treatment Market Size and Y-o-Y Growth
4.5.2 Chemotherapy Induced Neutropenia Treatment Market Absolute $ Opportunity
Chapter 5 Global Chemotherapy Induced Neutropenia Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
5.2.1 Antibiotic Therapy
5.2.2 Colony-Stimulating Factor Therapy
5.2.3 Granulocyte Transfusion
5.2.4 Splenectomy Procedure
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chemotherapy Induced Neutropenia Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Center
6.2.3 Diagnostic Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemotherapy Induced Neutropenia Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
9.6.1 Antibiotic Therapy
9.6.2 Colony-Stimulating Factor Therapy
9.6.3 Granulocyte Transfusion
9.6.4 Splenectomy Procedure
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Center
9.10.3 Diagnostic Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
10.6.1 Antibiotic Therapy
10.6.2 Colony-Stimulating Factor Therapy
10.6.3 Granulocyte Transfusion
10.6.4 Splenectomy Procedure
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Center
10.10.3 Diagnostic Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
11.6.1 Antibiotic Therapy
11.6.2 Colony-Stimulating Factor Therapy
11.6.3 Granulocyte Transfusion
11.6.4 Splenectomy Procedure
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Center
11.10.3 Diagnostic Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
12.6.1 Antibiotic Therapy
12.6.2 Colony-Stimulating Factor Therapy
12.6.3 Granulocyte Transfusion
12.6.4 Splenectomy Procedure
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Center
12.10.3 Diagnostic Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
13.6.1 Antibiotic Therapy
13.6.2 Colony-Stimulating Factor Therapy
13.6.3 Granulocyte Transfusion
13.6.4 Splenectomy Procedure
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Center
13.10.3 Diagnostic Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemotherapy Induced Neutropenia Treatment Market: Competitive Dashboard
14.2 Global Chemotherapy Induced Neutropenia Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Sanofi
14.3.3 Novartis AG
14.3.4 Baxter International
14.3.5 Teva Pharmaceuticals Industries
14.3.6 Apotex
14.3.7 Dr. Reddy’s Laboratory
14.3.8 Biogenomics Limited
14.3.9 Ligand Pharmaceuticals
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemotherapy Induced Neutropenia Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemotherapy Induced Neutropenia Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemotherapy Induced Neutropenia Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemotherapy Induced Neutropenia Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemotherapy Induced Neutropenia Treatment Market Size & Forecast, 2018-2028
4.5.1 Chemotherapy Induced Neutropenia Treatment Market Size and Y-o-Y Growth
4.5.2 Chemotherapy Induced Neutropenia Treatment Market Absolute $ Opportunity
Chapter 5 Global Chemotherapy Induced Neutropenia Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
5.2.1 Antibiotic Therapy
5.2.2 Colony-Stimulating Factor Therapy
5.2.3 Granulocyte Transfusion
5.2.4 Splenectomy Procedure
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chemotherapy Induced Neutropenia Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Center
6.2.3 Diagnostic Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemotherapy Induced Neutropenia Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
9.6.1 Antibiotic Therapy
9.6.2 Colony-Stimulating Factor Therapy
9.6.3 Granulocyte Transfusion
9.6.4 Splenectomy Procedure
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Center
9.10.3 Diagnostic Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
10.6.1 Antibiotic Therapy
10.6.2 Colony-Stimulating Factor Therapy
10.6.3 Granulocyte Transfusion
10.6.4 Splenectomy Procedure
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Center
10.10.3 Diagnostic Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
11.6.1 Antibiotic Therapy
11.6.2 Colony-Stimulating Factor Therapy
11.6.3 Granulocyte Transfusion
11.6.4 Splenectomy Procedure
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Center
11.10.3 Diagnostic Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
12.6.1 Antibiotic Therapy
12.6.2 Colony-Stimulating Factor Therapy
12.6.3 Granulocyte Transfusion
12.6.4 Splenectomy Procedure
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Center
12.10.3 Diagnostic Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Type
13.6.1 Antibiotic Therapy
13.6.2 Colony-Stimulating Factor Therapy
13.6.3 Granulocyte Transfusion
13.6.4 Splenectomy Procedure
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chemotherapy Induced Neutropenia Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Center
13.10.3 Diagnostic Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemotherapy Induced Neutropenia Treatment Market: Competitive Dashboard
14.2 Global Chemotherapy Induced Neutropenia Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Sanofi
14.3.3 Novartis AG
14.3.4 Baxter International
14.3.5 Teva Pharmaceuticals Industries
14.3.6 Apotex
14.3.7 Dr. Reddy’s Laboratory
14.3.8 Biogenomics Limited
14.3.9 Ligand Pharmaceuticals
Segments Covered in the Report
The global Chemotherapy Induced Neutropenia Treatment market has been segmented based on
By Types
The global Chemotherapy Induced Neutropenia Treatment market has been segmented based on
By Types
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
- Hospitals
- Ambulatory Surgical Center
- Diagnostic Centers
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Amgen
- Sanofi
- Novartis AG
- Baxter International
- Teva Pharmaceuticals Industries
- Apotex
- Dr. Reddy’s Laboratory
- Biogenomics Limited
- Ligand Pharmaceuticals
Our Clients
Related Reports
Some other reports from this category!
